Stanley G. Leung
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Stanley G. Leung has a total of 123 co-authors. Here are the top co-authors by number of shared publications:
- E. Alejandro Sweet-Cordero
University of California San Francisco 8 Division of Pediatric Oncology, Department of Pediatrics San Francisco, CA
50 shared publications - Leanne C. Sayles
Division of Pediatric Oncology, UCSF, San Francisco, United States of America
47 shared publications - Marcus R. Breese
University of California, San Francisco 3 Division of Pediatric Oncology San Francisco, California
47 shared publications - Alex G. Lee
University of California, San Francisco 2 San Francisco, CA
46 shared publications - Maria V. Pons Ventura
Division of Pediatric Oncology, Department of Pediatrics, University of California San Francisco, San Francisco, California
45 shared publications - Andrew S. Clugston
Division of Pediatric Oncology, Department of Pediatrics, University of California San Francisco, San Francisco, California
40 shared publications
Latest Publications
- Open Access
- 22 October 2026
- Published by American Society for Clinical Investigation in JCI Insight
STING agonism orchestrates myeloid-predominant tumor necrosis preceding T cell-dependent regression in osteosarcoma
An immunosuppressive, macrophage-rich tumor microenvironment (TME) is a barrier to immunotherapy across many cancers including osteosarcoma, where immunotherapy has largely failed. cGAS-STING agonism has been explored to inflame such tumors, yet the mechanisms of STING-mediated TME remodeling remain poorly understood, especially in sarcomas. Using multi-modal single cell analysis, we show that systemic STING agonism in osteosarcoma triggers a myeloid-predominant inflammatory response and rapid tumor necrosis, followed by a T cell-mediated response, immunologic memory, and long-term cure in some models. Within two hours of treatment, STING agonism induces pro-inflammatory interferon programs in tumor-associated macrophages and monocytes, with additional contributions from endothelial cells. Efficacy persists in the absence of tumor-intrinsic STING or IFNAR, confirming that the therapeutic axis resides within the host TME rather than the tumor cell compartment. While cGAS-STING is frequently repressed in human osteosarcoma models of aggressive disease, a STING activation gene signature predicts survival in newly diagnosed patients, suggesting that this pathway is engaged during tumor progression. Together, these data identify an opportunity to exploit the myeloid compartment of osteosarcoma with STING pathway therapies, charting a path forward for engaging the TME to secure long term cure in an aggressive malignancy still treated with highly toxic chemotherapy.
- 22 October 2026
- Published by American Society for Clinical Investigation in JCI Insight
Open AccessSTING agonism orchestrates myeloid-predominant tumor necrosis preceding T cell-dependent regression in osteosarcoma
An immunosuppressive, macrophage-rich tumor microenvironment (TME) is a barrier to immunotherapy across many cancers including osteosarcoma, where immunotherapy has largely failed. cGAS-STING agonism has been explored to inflame such tumors, yet the mechanisms of STING-mediated TME remodeling remain poorly understood, especially in sarcomas. Using multi-modal single cell analysis, we show that systemic STING agonism in osteosarcoma triggers a myeloid-predominant inflammatory response and rapid tumor necrosis, followed by a T cell-mediated response, immunologic memory, and long-term cure in some models. Within two hours of treatment, STING agonism induces pro-inflammatory interferon programs in tumor-associated macrophages and monocytes, with additional contributions from endothelial cells. Efficacy persists in the absence of tumor-intrinsic STING or IFNAR, confirming that the therapeutic axis resides within the host TME rather than the tumor cell compartment. While cGAS-STING is frequently repressed in human osteosarcoma models of aggressive disease, a STING activation gene signature predicts survival in newly diagnosed patients, suggesting that this pathway is engaged during tumor progression. Together, these data identify an opportunity to exploit the myeloid compartment of osteosarcoma with STING pathway therapies, charting a path forward for engaging the TME to secure long term cure in an aggressive malignancy still treated with highly toxic chemotherapy.
- Open Access
- 18 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S3 from Epigenetic and Transcriptional Programs Define Osteosarcoma Subtypes and Establish Targetable Vulnerabilities
Supplementary Table S3. TFs per subtype related to Figure 2.
- 18 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S3 from Epigenetic and Transcriptional Programs Define Osteosarcoma Subtypes and Establish Targetable Vulnerabilities
Supplementary Table S3. TFs per subtype related to Figure 2.
- Open Access
- 18 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S7 from Epigenetic and Transcriptional Programs Define Osteosarcoma Subtypes and Establish Targetable Vulnerabilities
Supplementary Table S7. Information about the patients related to Figure 5B and Supplementary Figure S5C.
- 18 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S7 from Epigenetic and Transcriptional Programs Define Osteosarcoma Subtypes and Establish Targetable Vulnerabilities
Supplementary Table S7. Information about the patients related to Figure 5B and Supplementary Figure S5C.
- Open Access
- 18 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S4 from Epigenetic and Transcriptional Programs Define Osteosarcoma Subtypes and Establish Targetable Vulnerabilities
Supplementary Table S4. SEs per PDX-cell line related to Figure 3.
- 18 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S4 from Epigenetic and Transcriptional Programs Define Osteosarcoma Subtypes and Establish Targetable Vulnerabilities
Supplementary Table S4. SEs per PDX-cell line related to Figure 3.
- Open Access
- 18 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S11 from Epigenetic and Transcriptional Programs Define Osteosarcoma Subtypes and Establish Targetable Vulnerabilities
Supplementary Table S11. Drug screen tested in the PDX-cell lines panel related to Supplementary Figure S8A.
- 18 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S11 from Epigenetic and Transcriptional Programs Define Osteosarcoma Subtypes and Establish Targetable Vulnerabilities
Supplementary Table S11. Drug screen tested in the PDX-cell lines panel related to Supplementary Figure S8A.
- Open Access
- 18 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S8 from Epigenetic and Transcriptional Programs Define Osteosarcoma Subtypes and Establish Targetable Vulnerabilities
Supplementary Table S8. IHC TMA quantification related to Figure 5E-5F.
- 18 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S8 from Epigenetic and Transcriptional Programs Define Osteosarcoma Subtypes and Establish Targetable Vulnerabilities
Supplementary Table S8. IHC TMA quantification related to Figure 5E-5F.
- Open Access
- 18 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S3 from Epigenetic and Transcriptional Programs Define Osteosarcoma Subtypes and Establish Targetable Vulnerabilities
Supplementary Figure S3 shows the superenhancer signatures and pathway analysis, related to Figure 3.
- 18 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S3 from Epigenetic and Transcriptional Programs Define Osteosarcoma Subtypes and Establish Targetable Vulnerabilities
Supplementary Figure S3 shows the superenhancer signatures and pathway analysis, related to Figure 3.
- Open Access
- 18 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from Epigenetic and Transcriptional Programs Define Osteosarcoma Subtypes and Establish Targetable Vulnerabilities
Supplementary Table S1. Summary of the samples used in this study related to Figure 1.
- 18 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from Epigenetic and Transcriptional Programs Define Osteosarcoma Subtypes and Establish Targetable Vulnerabilities
Supplementary Table S1. Summary of the samples used in this study related to Figure 1.
- Open Access
- 18 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from Epigenetic and Transcriptional Programs Define Osteosarcoma Subtypes and Establish Targetable Vulnerabilities
Supplementary Figure S2 shows the characterization of the enriched TF set per subtype, related to Figure 2.
- 18 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from Epigenetic and Transcriptional Programs Define Osteosarcoma Subtypes and Establish Targetable Vulnerabilities
Supplementary Figure S2 shows the characterization of the enriched TF set per subtype, related to Figure 2.
- Open Access
- 18 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S9 from Epigenetic and Transcriptional Programs Define Osteosarcoma Subtypes and Establish Targetable Vulnerabilities
Supplementary Table S9. Detailed peak and gene information from PDX- single cell multiome experiment related to Figure 6.
- 18 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S9 from Epigenetic and Transcriptional Programs Define Osteosarcoma Subtypes and Establish Targetable Vulnerabilities
Supplementary Table S9. Detailed peak and gene information from PDX- single cell multiome experiment related to Figure 6.